Clovis Oncology Announces Completion of Target Enrollment in the ATHENA Trial, a Phase 3 Maintenance Treatment Study in Front-line, Newly-Diagnosed Advanced Ovarian Cancer

• NASDAQ: $CLVS
• Notified: $7.16
• 16:06 EDT